Drugs / M1231
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04695847 | Jan 2021 → Jun 2023 | esophageal cancer, metastatic neoplasm, non-small cell lung carcinoma | EMD Serono Research & Development Institute, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-06-24 | Sutro Biopharma, Inc. | M1231: A First In-Class Bispecific ADC Targeting EGFR and MUC1 Presented by EMD Serono at American Association for Cancer Research (AACR) Virtual Meeting II on June 24, 2020 – Presentation sutrobio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M1231 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04695847 ↗ |